Corvus Pharmaceuticals CRVS Investment Proceeds
Investment Proceeds at other companies
Other financials
Where this comes from
Reported directly by Corvus Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities.
The official record: Corvus Pharmaceuticals’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Corvus Pharmaceuticals's investment proceeds.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Corvus Pharmaceuticals's investment proceeds?
- Corvus Pharmaceuticals (CRVS) reported investment proceeds of $16.98M in Q1 2026.
- How has Corvus Pharmaceuticals's investment proceeds changed year-over-year?
- Corvus Pharmaceuticals's investment proceeds increased by 41.7% year-over-year, from $11.99M to $16.98M.
- What is the long-term trend for Corvus Pharmaceuticals's investment proceeds?
- Over 4 years (2021 to 2025), Corvus Pharmaceuticals's investment proceeds has grown at a 28.4% compound annual growth rate (CAGR), from $30.92M to $84.13M.
- What does investment proceeds mean?
- Cash received from sales, maturities, and redemptions of investment securities across all categories.